Clinical Trial Update: Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C [Phase 4]

View source ↗

Summary

Phase 4 trial investigating individualized duration of pegylated interferon plus ribavirin for chronic hepatitis C (genotype 1) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Göteborg University | Conditions: Chronic Hepatitis C, Genotype 1 | Phase 4 | Status: COMPLETED